[ACCESSWIRE]
BAD HOMBURG, GERMANY / ACCESSWIRE / February 21, 2019 / Fresenius Medical Care, the world's largest provider of dialysis products and services, announced that it has filed the annual report 2018 under form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors" section as well as at the SEC's website, (www.sec.gov).
A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at [email protected].
The company also published a Facts & Figures 2018 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2018. In addition, the new Corporate Magazine, Company Profile as well as a Five-Year-Summary are available for download.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,928 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 333,331 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com and factsandfigures.fmc-ag.com.
Disclaimers
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Contact:
Dr. Dominik Heger
SVP & Head of Investor Relations & Corporate Communications
[email protected]
P. +49 6172 609 2601
SOURCE: Fresenius Medical Care
